NeuroSense Receives Nasdaq Delisting Notices for Minimum Bid Price & Market Value Requirements

summarizeSummary

NeuroSense Therapeutics received two Nasdaq notifications for failing to meet the minimum bid price and market value requirements, initiating a compliance period to avoid delisting.

check_boxKey Events

• Receipt of Nasdaq Notifications

  NeuroSense Therapeutics received two notification letters from Nasdaq on April 2, 2026, indicating non-compliance with continued listing requirements.

• Non-Compliance with Minimum Bid Price

  The company's ordinary shares traded below $1.00 for 30 consecutive business days (February 18 - March 31, 2026), violating Nasdaq Listing Rule 5550(a)(2).

• Non-Compliance with Market Value of Listed Securities (MVLS)

  The company's MVLS was below $35 million for 30 consecutive business days over the same period, violating Nasdaq Listing Rule 5550(b)(2).

• Compliance Period Established

  NeuroSense has 180 calendar days, until September 29, 2026, to regain compliance with both requirements. This requires the stock to close at or above $1.00 and the MVLS to be $35 million or more for a minimum of 10 consecutive business days.

auto_awesomeAnalysis

NeuroSense Therapeutics has received formal notifications from Nasdaq regarding non-compliance with both the minimum $1.00 bid price and the $35 million market value of listed securities (MVLS) requirements. This is a critical development, following closely on the heels of the company's 'going concern' warning reported in its 20-F filing on March 31, 2026. While these notifications do not have an immediate effect on trading, they signal a significant escalation of financial distress and pose a substantial threat to the company's Nasdaq listing. The company has until September 29, 2026, to regain compliance, which will likely require a reverse stock split or a substantial increase in market valuation, both challenging given the current financial situation. Failure to regain compliance could lead to delisting, severely impacting liquidity and investor confidence.